Clinical Trial Update: Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating darolutamide with or without androgen deprivation therapy as neoadjuvant treatment before definitive therapy in high-risk localized p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• Darolutamide (darolutamide)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Prostate Cancer | Phase 2 | Status: NOT_YET_RECRUITING